StockNews.com Begins Coverage on Organovo (NASDAQ:ONVO)

Investment analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Trading Up 1.7 %

NASDAQ:ONVO opened at $1.75 on Friday. Organovo has a twelve month low of $1.56 and a twelve month high of $21.96. The company has a market cap of $2.98 million, a PE ratio of -2.06 and a beta of 1.13. The company’s 50 day moving average is $4.09 and its two-hundred day moving average is $4.60.

Organovo (NASDAQ:ONVO) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($2.28) EPS for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.24. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. As a group, analysts expect that Organovo will post -0.77 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.